Healthcare·1 min read·Author: AP News
Celltrion wins FDA nod for new biosimilar candidate
U.S. regulators approved a Celltrion biosimilar, expanding the company's immunology portfolio.
Updated: Jul 11, 2026, 06:30 AM GMT-3
Koreabw AI
U.S. regulators approved a Celltrion biosimilar, expanding the company's immunology portfolio.
Celltrion received FDA approval for a biosimilar therapy, strengthening its U.S. commercial pipeline. Korean biopharma exporters continue to gain share in regulated markets through cost-competitive biologics.
Related companies
Where it matters
TagsCelltrionFDAbiosimilarbiotech
Related coverage
Healthcarebiz.heraldcorp.com
Celltrion Launches Omryklo in the US, Expanding Allergy Treatment Portfolio
Healthcarerttnews.com
Celltrion Launches OMLYCLO, First Interchangeable Omalizumab Biosimilar in U.S.
Healthcarebiz.chosun.com
Celltrion Launches First Omalizumab Biosimilar in the U.S.
Healthcareprnewswire.com